Skip to main content
    T

    Theriva Biologics Inc. (TOVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE MKT

    $0.14
    +0.00 (+1.14%)

    Market Cap: $6.42M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Theriva Biologics Inc. (TOVX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Theriva Biologics (TOVX) has a market cap of $6.42M and an enterprise value of $839.00K. It kept -2909.33% of revenue as net income over the last 12 months. Its share count is up 374.27% from a year earlier.

    Total Valuation

    Enterprise value is 86.94% below the market cap, as cash exceeds debt.

    Market Cap$6.42M
    Enterprise Value$839.00K
    Latest price (Nov 17, 2026)$0.14

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 536.05% a year over 2 years.

    Shares Outstanding45.89M
    Shares Change (YoY)+374.27%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+536.05%

    Valuation Ratios

    Sales and book value multiples are 21.7x and 0.6x.

    P/S Ratio21.7x
    Forward P/S21.4x
    P/B Ratio0.6x

    Price Statistics

    The stock is down 47.81% over 52 weeks and trades 30.00% below its 50-day average.

    Beta (1Y)2.49
    52-Week Change-47.81%
    1-Month Change-30.83%
    3-Month Change-37.18%
    6-Month Change-46.95%
    5-Year Change-99.84%
    10-Year Change-100.00%
    Total Return (1Y)-47.81%
    Total Return (3Y CAGR)-76.00%
    Total Return (5Y CAGR)-72.58%
    Max Drawdown (1Y)-65.85%
    Max Drawdown (3Y)-99.09%
    Sharpe Ratio (1Y)-0.55
    Correlation with SPY (1Y)0.33
    50-Day Average$0.20
    200-Day Average$0.24
    52-Week Range$0.14 to $0.49
    RSI (14 Days)27.9
    Average Volume (20 Days)5.31M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.21x current liabilities, and total debt is 0.27x shareholder equity.

    Current Ratio1.21x
    Quick Ratio1.21x
    Debt / Equity0.27x

    Returns and Efficiency

    Return on invested capital is -52.27% over the last 12 months, against a 5-year average of -64.75%.

    Return on Equity (ROE)-81.17%
    Return on Assets (ROA)-27.66%
    Return on Invested Capital (ROIC)-52.27%
    ROE (5Y Average)-79.66%
    ROA (5Y Average)-43.11%
    ROIC (5Y Average)-64.75%
    Asset Turnover0.01x

    Scores

    TOVX has an Altman Z-Score of -16.89, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-16.89
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $300.00K over the last 12 months is up 94.81% from the 12 months before.

    Revenue$300.00K
    Revenue Growth (YoY)+94.81%
    Gross Profit$273.00K
    Operating Income-$9.02M
    Pretax Income-$8.73M
    Net Income-$8.73M
    Reported EPS (TTM)-$0.25

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 34.06% of the $31.56M in total assets.

    Cash and Equivalents$8.47M
    Total Debt$2.89M
    Net Cash$5.59M
    Net Cash Per Share$0.12
    Working Capital$1.84M
    Shareholder Equity$10.75M
    Book Value Per Share$0.23
    Tangible Book Value-$8.20M
    Total Assets$31.56M
    Total Liabilities$20.81M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$11.28M
    FCF Per Share-$0.25
    Depreciation and Amortization$97.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -3006.33%.

    Gross Margin91.00%
    Operating Margin-3006.33%
    Pretax Margin-2909.33%
    Net Margin-2909.33%

    Dividends and Yields

    TOVX does not pay a dividend.

    Buyback Yield-136.30%
    Shareholder Yield-136.30%

    Stock Splits

    The last split was a 1-for-25 reverse split on Aug 26, 2024.

    Last Split DateAug 26, 2024
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TOVX

    What is TOVX's market cap?

    Theriva Biologics has a market cap of $6.42M. Its enterprise value, which adds debt and subtracts cash, is $839.00K.

    How many shares of TOVX are outstanding?

    Theriva Biologics has 45.89M shares outstanding. The count is up 374.27% from a year earlier.

    Does TOVX pay a dividend?

    No. Theriva Biologics does not pay a dividend.

    How much debt does TOVX have?

    Theriva Biologics has $2.89M of total debt and $8.47M of cash and equivalents, a net cash position of $5.59M.